Glycan microheterogeneity of α1-acid glycoprotein in sera and dialysates of patients on continuous ambulatory peritoneal dialysis

Fraeyman, Norbert; Velde, E J Van de; Belpaire, Frans; Lameire, Norbert

doi:10.1016/0009-8981(89)90316-1

Cited by 5 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased ORM expression has been associated with acute infection, chronic diseases, and different kinds of cancers [15,16]. Previous research showed that serum ORM was higher in ESRD patients before PD start compared with healthy controls in small series [17], but they do not classify different peritoneal transport characteristics. In this study, the result of western blot showed that ORM2 in LA&L group was higher than H, HA and NC group, clearly con rmed our proteomic data.…”

Section: Discussionmentioning

confidence: 99%

Orosomucoid can predict baseline peritoneal transport characteristics in peritoneal dialysis patients and reduce peritoneal proteins loss

Bao

Sun

Yang

et al. 2021

Journal of Proteomics

View full text Add to dashboard Cite

Background: Peritoneal dialysis (PD) is a kind of replacement therapies for end-stage renal disease (ESRD) patients. In the rst 4-8 weeks of PD therapy, the patients were given an empirical dialysis prescription due to unknown peritoneal transport characteristics.Methods: Proteomic analysis was used to identify serum biomarkers which can predict the baseline peritoneal transport characteristics.Results: A discovery set of serum samples from ESRD patients were collected. After 4-8 weeks of PD therapy, these patients were divided into three groups according to the peritoneal equilibration test (PET) results: high (H), high average (HA), low average and low (LA&L) transporters. A total of 1051 differential proteins were screened by nano High Performance Liquid Chromatography -Mass Spectrometry / Mass Spectrometry (Nano HPLC-MS/MS). The top two proteins among different peritoneal transport characteristics were Orosomucoid 2 (ORM2) and C-reactive protein (CRP). To verify the above biomarkers, a larger population of PD patients were enrolled. Immunoturbidimetric assay showed that CRP was signi cantly elevated in H group than LA&L group, consistent with the result of proteomic analysis. Western blot validated that ORM2 in serum was increased in LA&L group compared with H and HA group. The expression of ORM2 in peritoneum also altered progressively in three groups. At last, supplying exogenous ORM could actually change peritoneal substances transport by reducing peritoneal proteins loss, without causing an excessive pro-in ammatory response in mice.Conclusions: Serum ORM2 and CRP could be used as biomarkers to predict the baseline peritoneal transport characteristics, so as to guide the early PD treatment. ORM also raised the possibility of decreasing peritoneal proteins loss in PD patients. BackgroundPeritoneal dialysis (PD) is an effective, convenient and safe treatment for end-stage renal disease (ESRD) patients. PD therapy implies a peritoneal catheter set in peritoneal cavity, with a long-term glucose dialysate exchange to eliminate toxins.Peritoneal equilibration test (PET) developed by Twardowski[1] divided the peritoneal transport characterics as low (L), low average (LA), high average (HA), and high (H). Patients with higher transport characteristics need shorter dialysate dwell times, and have poorer nutrition status and prognosis as a signi cant independent risk factor for death [2][3][4]. The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines suggest that the rst PET should be performed 4-8 weeks after PD start. During this waiting period, the patients was given an empirical dialysis prescription due to unknown peritoneal transport characteristics. If we nd biomarkers to predict the baseline peritoneal transport characteristics before PD commencement, we could give an accurate PD prescription as soon as PD start instead of waiting for 4-8 weeks.The peritoneal transport characteristics change with dialysis vintage and peritonitis episodes after PD start [5]. However, before PD start, the baseline pe...

show abstract

Section: Discussionmentioning

confidence: 99%

Orosomucoid can predict baseline peritoneal transport characteristics in peritoneal dialysis patients and reduce peritoneal proteins loss

Bao

Sun

Yang

et al. 2021

Journal of Proteomics

View full text Add to dashboard Cite

show abstract

“…It consists of a single polypeptide chain bearing 5 glycosylation sites to which bi-, tri-or tetra-antennary oligosac charide chains can be attached. In crossed immunoaffinity electrophoresis (Cl AE), this microheterogeneity is reflected by the existence of 4 fractions which differ in their reactivity with free concanavalin A (ConA) [8], Changes in serum microheterogeneity have been reported in chronic renal failure [3] and during dialysis [3,9], but no data on urinary microheterogeneity have been published.…”

Section: Introductionmentioning

confidence: 99%

Serum and Urinary Alpha-1 Acid Glycoprotein in Chronic Renal Failure

Vasson¹,

Baguet

Arveiller

et al. 1993

Nephron

View full text Add to dashboard Cite

The concentration and concanavalin A (ConA)-dependent microheterogeneity of serum and urinary α_1-acid glycoprotein (AGP) were studied in patients with various degrees of renal impairment and compared with healthy control values. Serum concentrations of AGP were significantly higher in hemodialyzed and uremic patients than in the control subjects (1.54 ± 0.42 g/l, p < 0.05, and 1.20 ± 0.40 g/l, p < 0.05, respectively, versus 0.83 ± 0.17 g/l). There was a similar increase in serum α₁-protease inhibitor and haptoglobin concentrations in the uremic patients (r = 0.87 and r = 0.70; p < 0.001). Urinary concentrations of AGP were also significantly higher in the hemodialyzed and uremic patients than in the control subjects, despite wide variability in the patients (20 ± 14 mg/24 h, p < 0.05, and 126 ± 160 mg/24 h, p < 0.05, respectively, versus 3 ± 1 mg/24 h). AGP clearance was significantly higher in the uremic patients than in the hemodialyzed patients (p < 0.01) and the control subjects (p < 0.01). The proportions of strongly ConA-reactive AGP fractions were higher in the serum of the hemodialyzed (18.6 ± 5.2%; p < 0.05) and uremic patients (18.1 ± 5.3%; p < 0.05) than in the control subjects (14.5 ± 2.5%). There was a similar difference in the urine samples (26.7 ± 8.2%, p < 0.01; 20.1 ± 6.2%, p < 0.0l, respectively, versus 10.3 ± 4.8%), with also a significant difference between the hemodialyzed and uremic patients (p < 0.05). Moreover, there was a correlation between serum and urinary levels of the strongly ConA-reactive AGP fractions in the uremic patients (r = 0.85). These results show that serum and urinary levels of biantennary AGP glycans are elevated in chronic renal failure not yet requiring hemodialysis, changes that did not seem to depend on the duration or the degree of renal failure. This reflects a chronic inflammatory state, probably due to altered cytokine secretion (principally interleukin-1, interleukin-6 and tumor necrosis factor-α).

show abstract